Literature DB >> 1554117

Efficacy and safety of tramadol versus morphine for moderate and severe postoperative pain with special regard to respiratory depression.

R J Houmes1, M A Voets, A Verkaaik, W Erdmann, B Lachmann.   

Abstract

The analgesic efficacy and safety of tramadol and morphine were compared in a double-blind, randomized study of 150 female patients after gynecologic surgery. As required, patients could receive up to three intravenous doses of either 50 mg of tramadol or 5 mg of morphine within a period of 6 h. Pain intensity (verbal response score) was recorded before injection and at 0.5, 1, 2, 3, 5, and 6 h after the initial dose; at these times, pain relief was also assessed. Oxygen saturation was monitored continuously by pulse oximetry for at least 30 min after each injection. In 13.3% of the morphine group (but in none of the tramadol group) transcutaneous pulse oxygen saturation decreased to less than 86%; in 50% of these patients the decrease occurred after only the first 5 mg of morphine. Both drugs produced acceptable analgesia, and there were no clinically significant adverse events. In demonstrating the absence of clinically relevant respiratory depression with tramadol, we underline its safety for postoperative pain relief.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554117     DOI: 10.1213/00000539-199204000-00007

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  35 in total

Review 1.  The role of tramadol in cancer pain treatment--a review.

Authors:  Wojciech Leppert; Jacek Łuczak
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

2.  The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.

Authors:  Diana Vivian Atigari; Kelly Frances Paton; Rajendra Uprety; András Váradi; Amy Frances Alder; Brittany Scouller; John H Miller; Susruta Majumdar; Bronwyn Maree Kivell
Journal:  Neuropharmacology       Date:  2020-12-28       Impact factor: 5.250

3.  PharmGKB summary: tramadol pathway.

Authors:  Li Gong; Ulrike M Stamer; Mladen V Tzvetkov; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-07       Impact factor: 2.089

Review 4.  [Tramadol in acute pain].

Authors:  K A Lehmann
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 5.  [Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance].

Authors:  M Cossmann; C Kohnen; R Langford; C McCartney
Journal:  Drugs       Date:  1997       Impact factor: 9.546

6.  Evaluation of the analgesic effects of oral and subcutaneous tramadol administration in red-eared slider turtles.

Authors:  Bridget B Baker; Kurt K Sladky; Stephen M Johnson
Journal:  J Am Vet Med Assoc       Date:  2011-01-15       Impact factor: 1.936

7.  A comparison of epidural tramadol and epidural morphine for postoperative analgesia.

Authors:  A Baraka; S Jabbour; M Ghabash; A Nader; G Khoury; A Sibai
Journal:  Can J Anaesth       Date:  1993-04       Impact factor: 5.063

Review 8.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

9.  Ultra low-dose naloxone and tramadol/acetaminophen in elderly patients undergoing joint replacement surgery: a pilot study.

Authors:  Ngozi N Imasogie; Sudha Singh; James T Watson; Debbie Hurley; Patricia Morley-Forster
Journal:  Pain Res Manag       Date:  2009 Mar-Apr       Impact factor: 3.037

10.  A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis.

Authors:  C Thorne; A D Beaulieu; D J Callaghan; W F O'Mahony; J M Bartlett; R Knight; G R Kraag; R Akhras; P S Piraino; J Eisenhoffer; Z Harsanyi; A C Darke
Journal:  Pain Res Manag       Date:  2008 Mar-Apr       Impact factor: 3.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.